Masimo’s Strategic Initiatives and Financial Outlook Support Buy Rating

In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Masimo (MASI – Research Report), with a price target of $193.00.

Marie Thibault has given her Buy rating due to a combination of factors that highlight Masimo’s strategic initiatives and financial outlook. The company is actively working on expanding its market share in high-growth areas by introducing new monitoring categories and updating its existing technology with AI enhancements. These efforts are expected to drive future growth and align with the company’s focus on innovation within the healthcare sector.
Additionally, Masimo’s financial health is underscored by its strong cash flow generation and a clear path to achieving approximately 30% margins. The transition of manufacturing operations from Mexico to Malaysia is anticipated to enhance gross margins, while maintaining stable R&D investments. These strategic moves, coupled with the potential for strategic acquisitions, provide a solid foundation for the company’s valuation, supporting the Buy rating with a price target of $193.

According to TipRanks, Thibault is a 4-star analyst with an average return of 3.1% and a 41.34% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Dexcom, iCAD, and Atricure.